The Role of Circular RNAs in Regulating Resistance to Cancer Immunotherapy: Mechanisms and Implications

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 May 2

PMID 38697964

Authors

Yu Ma

Ting Wang

Xudong Zhang

Pinghan Wang

Fangyi Long

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy has rapidly transformed cancer treatment, yet resistance remains a significant hurdle, limiting its efficacy in many patients. Circular RNAs (circRNAs), a novel class of non-coding RNAs, have emerged as pivotal regulators of gene expression and cellular processes. Increasing evidence indicates their involvement in modulating resistance to cancer immunotherapy. Notably, certain circRNAs function as miRNA sponges or interact with proteins, influencing the expression of immune-related genes, including crucial immune checkpoint molecules. This, in turn, shapes the tumor microenvironment and significantly impacts the response to immunotherapy. In this comprehensive review, we explore the evolving role of circRNAs in orchestrating resistance to cancer immunotherapy, with a specific focus on their mechanisms in influencing immune checkpoint gene expression. Additionally, we underscore the potential of circRNAs as promising therapeutic targets to augment the effectiveness of cancer immunotherapy. Understanding the role of circRNAs in cancer immunotherapy resistance could contribute to the development of new therapeutic strategies to overcome resistance and improve patient outcomes.

Citing Articles

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer.

Pecoraro G, Leone I, Nuzzo S, Negueruela S, Smaldone G, Buono L Front Oncol. 2025; 15:1502405.

PMID: 40008007 PMC: 11850525. DOI: 10.3389/fonc.2025.1502405.

Interferon Gamma Receptor 2 Collaborates With Circular RNA/MicroRNA to Modulate Programmed Cell Death-Ligand 1 Levels in Nasopharyngeal Carcinoma.

Guan G, Fu Z, Zhang D, Guo Y, Guo F, Wan Y World J Oncol. 2024; 15(6):929-941.

PMID: 39697423 PMC: 11650609. DOI: 10.14740/wjon1994.

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.

CircRNome-wide characterisation reveals the promoting role of circAATF in anti-PD-L1 immunotherapy of gallbladder carcinoma.

Wang Y, Li S, Bo X, Li Y, Wang C, Nan L Clin Transl Med. 2024; 14(10):e70060.

PMID: 39428382 PMC: 11491271. DOI: 10.1002/ctm2.70060.

Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance.

Wang H, Fleishman J, Cheng S, Wang W, Wu F, Wang Y Mol Cancer. 2024; 23(1):177.

PMID: 39192329 PMC: 11348582. DOI: 10.1186/s12943-024-02088-7.

References

Crispen P, Kusmartsev S . Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2019; 69(1):3-14. PMC: 6949323. DOI: 10.1007/s00262-019-02443-4. View

Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J . Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:562315. PMC: 8085334. DOI: 10.3389/fonc.2021.562315. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y . Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023; 22(1):55. PMC: 10024440. DOI: 10.1186/s12943-023-01759-1. View

Zhang L, Song X, Chen X, Wang Q, Zheng X, Wu C . Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression. Int J Biol Sci. 2019; 15(5):1091-1103. PMC: 6535790. DOI: 10.7150/ijbs.31533. View

Blach J, Wojas-Krawczyk K, Nicos M, Krawczyk P . Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer. Int J Mol Sci. 2021; 22(16). PMC: 8396490. DOI: 10.3390/ijms22169030. View

Tan S, Gou Q, Pu W, Guo C, Yang Y, Wu K . Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 2018; 28(6):693-695. PMC: 5993747. DOI: 10.1038/s41422-018-0033-7. View

Shen Z, Zhou L, Zhang C, Xu J . Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 2019; 468:88-101. DOI: 10.1016/j.canlet.2019.10.006. View

Ge W, Chi H, Tang H, Xu J, Wang J, Cai W . Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis. Aging (Albany NY). 2021; 13(22):24560-24579. PMC: 8660608. DOI: 10.18632/aging.203576. View

10.

Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J . CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mA modification in hepatocellular carcinoma. Mol Ther Oncolytics. 2022; 24:755-771. PMC: 8908059. DOI: 10.1016/j.omto.2022.02.021. View

11.

Gao J, Ao Y, Zhang L, Deng J, Wang S, Wang H . Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. J Exp Clin Cancer Res. 2022; 41(1):295. PMC: 9547453. DOI: 10.1186/s13046-022-02505-z. View

12.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

13.

Chen L, Yang L . Regulation of circRNA biogenesis. RNA Biol. 2015; 12(4):381-8. PMC: 4615371. DOI: 10.1080/15476286.2015.1020271. View

14.

Zou H, Mou X, Zhu B . Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Glob Chall. 2023; 7(1):2200094. PMC: 9818137. DOI: 10.1002/gch2.202200094. View

15.

Ashwal-Fluss R, Meyer M, Pamudurti N, Ivanov A, Bartok O, Hanan M . circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56(1):55-66. DOI: 10.1016/j.molcel.2014.08.019. View

16.

Li Z, Huang C, Bao C, Chen L, Lin M, Wang X . Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015; 22(3):256-64. DOI: 10.1038/nsmb.2959. View

17.

Wang Z, Wu X . Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Cancer Med. 2020; 9(21):8086-8121. PMC: 7643687. DOI: 10.1002/cam4.3410. View

18.

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T . Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020; 14(3):539-555. PMC: 7053238. DOI: 10.1002/1878-0261.12629. View

19.

Shalhout S, Miller D, Emerick K, Kaufman H . Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023; 20(3):160-177. DOI: 10.1038/s41571-022-00719-w. View

20.

Adamik J, Butterfield L . What's next for cancer vaccines. Sci Transl Med. 2022; 14(670):eabo4632. DOI: 10.1126/scitranslmed.abo4632. View